The hidden leak in many fertility pathways is not simply failed treatment. It is unexplained failure without a sharper male factor investigation.
For decades, fertility pathways have carried a comfortable but incomplete assumption: if semen concentration, motility and morphology look acceptable, the male contribution has largely been assessed.
That assumption may be operationally convenient, but it can be clinically and commercially expensive. Standard semen analysis describes visible parameters. It does not directly interrogate the integrity of the sperm DNA payload being delivered into the reproductive process.
In a modern IVF clinic, this gap can show up as repeat failed cycles, recurrent miscarriage discussions, poor embryo development, rising patient anxiety, dissatisfied couples, more second opinions and avoidable patient attrition.
This page helps clinics quantify the financial case before a pilot, while keeping clinical claims appropriately cautious and evidence aligned.
Model patient price, Examen transfer price, clinic admin costs, logistics costs and net margin per test.
Estimate the commercial impact of retaining appropriate patients after failure through clearer male factor counselling.
Compare a shared Central Hub model against a Clinic Owned Direct Shipper model to Belfast.
For clinical leadership
- Supports more complete male factor investigation where clinically appropriate.
- Helps structure conversations after unexplained failure, recurrent loss or poor embryo development.
- Positions advanced Sperm DNA Testing as an evidence based pathway support tool, not as a guaranteed outcome claim.
- Strengthens multidisciplinary fertility decision making across clinician, embryology and andrology teams.
For commercial leadership
- Creates a premium diagnostic revenue stream without requiring an in house specialist laboratory build.
- Improves the quality of patient counselling after unsuccessful cycles, which can protect retention.
- Allows clinics to test a pilot model before wider rollout.
- Gives finance teams transparent assumptions for pricing, logistics, margin and annualised opportunity.
Use this calculator to estimate direct diagnostic margin, annualised revenue potential and the value of reducing avoidable post failure pathway dropout. All figures are editable and should be replaced with clinic specific inputs.
Use this calculator to compare operational cost per test, shipper utilisation, patient retail price, clinic margin and pilot viability for two logistics models to Belfast.
| Metric | Central Hub Model | Clinic Owned Direct Shipper |
|---|---|---|
| Monthly Examen tests | ||
| Monthly vials including buffer | ||
| Shipper utilisation | ||
| International freight per test | ||
| Local courier, handling and export admin per test | ||
| Clinic admin / consumables per test | ||
| Total logistics and operational cost per test | ||
| All in cost to clinic including Examen transfer | ||
| Patient retail price | ||
| Tax / card fee deduction per test | ||
| Clinic net margin per test | ||
| Clinic net margin % | ||
| Monthly net clinic margin | ||
| Decision status |